Shorts

0:34
MRD Alerts: How Soon Will Imaging Confirm Progression?
7 months ago
by
Rutika Mehta, MD, MPH

0:33
The Future of Targeted Therapy in Mesothelioma
7 months ago
by
Michael Offin, MD

0:39
Dr Kittai on The Role of MRD Testing in CLL
7 months ago
by
Adam Kittai, MD(+1 more)

0:33
How Proton Therapy is Revolutionizing Cancer Treatment
7 months ago
by
Charles Simone, MD

0:41
Why Patient Preference Matters in CLL Treatment
7 months ago
by
Adam Kittai, MD(+1 more)

1:00
Low ctDNA May Signal Aggressive Tumor in Head and Neck Cancer
7 months ago
by
Catherine T. Haring, MD

1:03
The Biggest Unmet Needs in Lung Cancer
7 months ago
by
Adam Schoenfeld, MD

0:34
Talking MRD and ctDNA With Patients
7 months ago
by
Rutika Mehta, MD, MPH

0:30
Who Should Get Neoadjuvant Therapy in RCC
7 months ago
by
Naomi Haas, MD

0:30
Don't Believe The Google Prognosis: New Hope For Glioblastoma
7 months ago
by
Chibawanye Ene, MD, PhD

0:32
Why We Need To Look Outside the Brain to Treat Tumors
7 months ago
by
Chibawanye Ene, MD, PhD

0:44
Adjuvant Therapy in Non-Clear Cell RCC
7 months ago
by
Naomi Haas, MD

0:52
The Prognostic Potential of MRD/ctDNA in Metastatic GE Cancer
7 months ago
by
Rutika Mehta, MD, MPH

0:50
Don't Over-Treat Based on Risk Scores
7 months ago
by
Rami Komrokji, MD

0:17
Targeted: On Location at Memorial Sloan Kettering Cancer Center
7 months ago
by
Helena Yu, MD(+2 more)

0:42
Understanding MDS Staging and the Path to Cure
7 months ago
by
Rami Komrokji, MD

0:49
ctDNA & MRD: Smarter Therapy Decisions in Metastatic GE Cancer
7 months ago
by
Rutika Mehta, MD, MPH

0:46
Combining CELMoDs and Cell Therapies in Myeloma
7 months ago
by
Sagar Lonial, MD, FACP

0:49
Balancing Therapy and QOL With MRD Testing in Gastroesophageal Cancer
7 months ago
by
Rutika Mehta, MD, MPH

0:35
A Mass in the Right-Sided Kidney
7 months ago
by
Pavlos Msaouel, MD, PhD

0:47
Menin Inhibitors Could Redefine AML Frontline Therapy
8 months ago
by
Richard Stone, MD

0:42
Setting a New Standard in EGFR+ Lung Cancer
8 months ago
by
Nicolas Girard, MD, PhD

0:46
Survival With Bispecific Combo Favors Early Use in Myeloma
8 months ago
by
Roberto Mina, MD

0:33
The Key Test to Confirm RMC Diagnosis is Immunohistochemistry for INI1
8 months ago
by
Pavlos Msaouel, MD, PhD

0:48
The Need for HRR Mutation Testing in Prostate Cancer
8 months ago
by
Sandy Srinivas, MD

1:27
Are We Nearing the End of 7+3 Alone in AML?
8 months ago
by
Richard Stone, MD

0:32
One Analogy Doesn't Work for Every Patient
8 months ago
by
Sanjay K. Juneja, MD(+1 more)

0:34
Managing Toxicities in Patients on Erdafitinib Therapy
8 months ago
by
Thomas W. Flaig, MD

0:59
The Power of a Gut Feeling in Cancer Care
8 months ago
by
Sanjay K. Juneja, MD

0:38
New Frontiers in Urothelial Carcinoma
8 months ago
by
Thomas W. Flaig, MD
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC
2
Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML
3
FDA Approves Giredestrant Plus Everolimus in ESR1-Mutated Breast Cancer
4
FDA Fast Tracks Elticertinib for Previously Treated EGFR Exon 20 NSCLC
5
